RT Journal Article
SR Electronic
T1 340 TGFβDNRII genetically-engineered TIL: characterizing final drug product from a phase I clinical trial
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A389
OP A389
DO 10.1136/jitc-2023-SITC2023.0340
VO 11
IS Suppl 1
A1 Adlerz, Katrina
A1 Jafari, Ellgar
A1 Zulovich, Jane
A1 Li, Yue
A1 Sakellariou-Thompson, Donald
A1 Forget, Marie-Andrée
A1 Balasubramanian, Priya
A1 Bernatchez, Chantale
A1 Amaria, Rodabe
A1 Bock, Jason
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A389.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.